However, we observed a significantly higher proportion of proliferating immune cells in HR− as compared with HR+ tumours, except for Foxp3+ and consistently observed a numerically higher percentage of proliferating immune cells in basal-like tumours and HER2-enriched tumours and a numerically lower percentage of proliferating immune cells in luminal tumours. The gene discussed is ERBB2; the disease is neoplasm.